Prostate Cell News 9.32 August 24, 2018 | |
| |
TOP STORYResearchers screened a library of epigenetic inhibitors for their ability to render castration-resistant prostate cancer cells sensitive to enzalutamide and found that EZH2 inhibitors specifically potentiated enzalutamide-mediated inhibition of proliferation. Combination treatment with antisense oligonucleotides targeting EZH2 and androgen regeptor transcripts inhibited prostate cancer cell growth in vitro and in vivo better than single agents. [Cancer Res] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Investigators showed that up-regulation of miR-17-3p remarkably sensitized prostate cancer cells to ionizing radiation (IR). miR-17-3p mediated dysfunction of mitochondrial antioxidants apparently sensitizing IR therapy was manifested in vitro and in vivo. [Mol Ther Nucleic Acids] Abstract | Full Article Conditional genetic deletion of E-cadherin, a key component of adherens junctions, in a mouse model resulted in loss of prostate luminal cell polarity and randomization of spindle orientations. E-cadherin ablation caused prostatic hyperplasia which progressed to invasive adenocarcinoma. [PLoS Genet] Full Article Trefoil factor family 3 (TFF3)-silenced cells showed suppressed tumor cell growth and migration. After TFF3 silencing, the expression of the mitochondrial proapoptotic proteins, cytochrome C and Smac/DIABLO, was elevated, and these proteins were released from the mitochondria to the cytosol. [Exp Mol Med] Full Article The improved pharmacokinetics of Evans blue-prostate-specific membrane antigen (PSMA)-617 resulted in significantly higher accumulation in PSMA+ tumors and highly effective radiotherapeutic efficacy. [Bioconjug Chem] Abstract | Graphical Abstract Scientists discovered that loss-of-function of TP53 could promote the development of resistance of castration in prostate cancer cells via both transiently potentiating androgen-independent cell growth and facilitating the occurrence of genome instability. [Sci Rep] Full Article Long Non-Coding RNA MYU Promotes Prostate Cancer Proliferation by Mediating the miR-184/C-Myc Axis Long non-coding RNA MYU upregulated c-Myc by competitively binding miR-184 and then induced the proliferation of prostate cancer. MYU knockdown impaired prostate cancer cell growth and migration as shown from cell viability, colony formation, transwell and wound healing assays. [Oncol Rep] Abstract A molecular mechanism study demonstrated that NOL8 promoted the migration and colony formation of cancer cells by activating beta-catenin/TCF signaling. [Chem Biol Interact] Abstract Knock down of cell division cycle-associated protein 1 (CDCA1) significantly inhibited the growth and promoted the apoptosis of prostatic cancer cells. In vivo, the tumor size was reduced in NOD/SCID mice treated with pH low insertion peptide (pHLIP)-CDCA1-siRNA compared to the CDCA1-siRNA and the bioluminescent signal of Cy5-pHLIP-CDCA1-siRNA was focused detected in the tumor site. [Biochem Biophys Res Commun] Abstract Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News. | |
| |
REVIEWSThe authors provide a critical literature review of the current basic science and clinical evidence for the interaction between estrogens and prostate cancer. [Prostate Cancer Prostatic Dis] Abstract Visit our reviews page to see a complete list of reviews in the prostate cell research field. | |
| |
INDUSTRY NEWSInitiation of Biosceptre’s Phase I Clinical Trial for First-in-Class Oncology Vaccine BIL06v Biosceptre has initiated its Phase I clinical trial of the peptide vaccine BIL06v, with the first patient treated at the initial trial site on 16th of August 2018. [Biosceptre] Press Release Pfizer Inc. and Astellas Pharma Inc. announced amendments to the protocols for two registrational Phase III trials, ARCHES and EMBARK, designed to evaluate the safety and efficacy of XTANDI® in men with hormone-sensitive prostate cancer. These amendments accelerate timelines for the anticipated primary completion dates of both trials. [Pfizer Inc.] Press Release The Prostate Cancer Foundation and the Movember Foundation Announce 2018 Challenge Award Winners The Prostate Cancer Foundation (PCF) and the Movember Foundation announced four new Movember Foundation-PCF Challenge Award teams at some of the world’s leading academic research institutions will receive a total of $3.5 million to support cross-disciplinary pioneering research toward the goal of finding a cure for prostate cancer. [Movember Canada] Press Release | |
| |
POLICY NEWSSenate Approves $2B Boost for NIH in $850B+ Spending Bill For the fourth year in a row, the Senate has approved a significant increase in funding for the National Institutes of Health (NIH). [Fierce Biotech] Editorial AAAS Insiders Petition to Revoke Honors of Sexual Harassers Using the hashtag #TimesUpAAAS, 36 researchers recognized by the American Association for the Advancement of Science (AAAS) for their science communication work posted an open letter asking the society not to bestow honors on those “who have engaged in harassment and discrimination.” [The Scientist] Editorial Former CDC Director Tom Frieden Arrested on Sexual Misconduct Charges Dr. Thomas Frieden, the former head of the Centers for Disease Control and Prevention (CDC), was arrested and charged with sexual abuse and harassment, according to the New York Police Department. [STAT News] Editorial
| |
EVENTSNEW Stem Cells & Organoids in Development & Disease Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellowship – Prostate Cancer Progression (Aarhus University) Postdoctoral Position – Translational Cancer Research (University of California, Davis) Postdoctoral Fellow/Research Scientist – Prostate Cancer (Università della Svizzera italiana) Research Fellow – Personalized Medicine of Anti-Cancer Therapy (Mayo Clinic) Senior Research Scientist – Prostate Cancer Research (University of California, San Francisco) Postdoctoral Position – Prostate Cancer (The University of Minnesota, Twin Cities) Clinical Fellow – Prostate Cancer Biology (Cancer Research UK Manchester Institute) Postdoctoral Position – Tumor Ecosystem Research (University of Zurich) Postdoctoral Felllow – Non-Coding RNA & Cancer Research (University of Toronto) Research Fellowship – Prostate Cancer Pathology (Weill Cornell Medicine) Postdoctoral Fellow – Prostate Cancer Metastasis Research (Oregon Health & Science University) Research Fellow – Prostate Cancer (Sechenov University) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Prostate Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|